false000167377200016737722024-05-222024-05-22

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 22, 2024

 

 

RAPT Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-38997

47-3313701

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

561 Eccles Avenue

 

South San Francisco, California

 

94080

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (650) 489-9000

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.0001 par value per share

 

RAPT

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 5.07 Submission of Matters to a Vote of Holders.

On May 22, 2024, RAPT Therapeutics, Inc. (the “Company”) held its 2024 annual meeting of stockholders (the “Annual Meeting”). The following is a brief description of each matter voted upon at the Annual Meeting, as well as the number of votes cast for and against each matter, and if applicable, the number of abstentions and broker non-votes with respect to each matter. A more complete description of each matter is described in more detail in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 5, 2024.

1.

Election of Directors

 

 

 

 

 

 

 

 

Director Name

 

Votes For

Votes
Withheld

Broker
Non-Votes

William J. Rieflin

23,182,856

885,082

4,885,783

Linda Kozick

 

22,177,799

 

1,890,139

 

4,885,783

Lori Lyons-Williams

22,257,340

1,810,598

4,885,783

 

The Class II director nominees were elected to hold office until the Company’s 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified.

2.

Ratification of Selection of Independent Registered Public Accounting Firm

 

 

 

 

 

 

 

 

Firm

 

Votes For

Votes
Against

 

Abstentions

Ernst & Young LLP

28,886,770

24,185

42,766

The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

RAPT Therapeutics, Inc.

 

 

 

 

Date:

May 23, 2024

By:

/s/ Rodney Young

 

 

 

Rodney Young
Chief Financial Officer

 

v3.24.1.1.u2
Document And Entity Information
May 22, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 22, 2024
Entity Registrant Name RAPT Therapeutics, Inc.
Entity Central Index Key 0001673772
Entity Emerging Growth Company true
Entity File Number 001-38997
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 47-3313701
Entity Address, Address Line One 561 Eccles Avenue
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code (650)
Local Phone Number 489-9000
Entity Information, Former Legal or Registered Name N/A
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol RAPT
Security Exchange Name NASDAQ
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more RAPT Therapeutics Charts.
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more RAPT Therapeutics Charts.